Vernakalant: A novel agent for the termination of atrial fibrillation

American Journal of Health-System Pharmacy

Volumn 67, Issue 14, 2010, Pages 1157-1164

  Finnin, Miki ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Atrial fibrillation; Cardiac drugs; Mechanism of action; Pharmacokinetics; Toxicity; Vernakalant

Indexed keywords

AMIODARONE; DOFETILIDE; FLECAINIDE; IBUTILIDE; PLACEBO; PROPAFENONE; SOTALOL; VERNAKALANT; ANISOLE DERIVATIVE; ANTIARRHYTHMIC AGENT; POTASSIUM CHANNEL BLOCKING AGENT; PYRROLIDINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; AREA UNDER THE CURVE; BRADYCARDIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART RATE VARIABILITY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LUNG EDEMA; NAUSEA; PARESTHESIA; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SINUS BRADYCARDIA; SINUS RHYTHM; SNEEZING; SODIUM CURRENT; TASTE DISORDER; TRANSIENT ISCHEMIC ATTACK; FOOD AND DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TIME; UNITED STATES;

ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; INFUSIONS, INTRAVENOUS; POTASSIUM CHANNEL BLOCKERS; PYRROLIDINES; SODIUM CHANNEL BLOCKERS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77957686713     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp080501     Document Type: Review

References (47)

1. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92:17-40. (Pubitemid 350182405)
2. McDonald AJ, Pelletier AJ, Ellinor PT et al. Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. Ann Emerg Med. 2008; 51:58-65.
3. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285:2370-5. (Pubitemid 32424106)
4. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114:119-25.
5. Kannel WB, Wolf PA, Benjamin EJ et al. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. Am J Cardiol. 1998; 82:2N-9N.
6. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001; 32:803-8.
7. Le Heusey JY, Paziaud O, Piot O et al. Cost of care distribution in atrial fibrillation patients: CPCAF study. Am Heart J. 2004; 147:121-6. (Pubitemid 38037407)
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-8.
9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987; 147:1561-4. (Pubitemid 17138836)
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449-57.
11. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995; 155:469-73.
12. Brendel J, Peukert S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr Med Chem. 2003; 1:273-87.
13. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs. 2007; 16:519-32. (Pubitemid 46554469)
14. + channel current. Circ Res. 1993; 73:210-6.
15. Amos GJ, Wettwer E, Metzger F et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol (Lond). 1996; 491:31-50. (Pubitemid 26059547)
16. Heidbüchel H, Vereecke J, Carmeliet E. Three different potassium channels in human atrium. Circ Res. 1990; 66:1277-86.
17. The AFFIRM first antiarrhythmic drug substudy investigators. Maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2003; 42:20-9.
18. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities, and therapeutic considerations. Drugs. 1994; 48:345-71.
19. Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol. 1987; 59:32E-37E.
20. Coplen SE, Antman EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation. 1990; 82:1106-16.
21. Lafuente C, Mouly S, Longas-Tejero MA et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation. Arch Intern Med. 2006; 166:719-28.
22. Radford MD, Evans DW. Long-term results of DC reversion of atrial fibrillation. Br Heart J. 1968; 30:91-6.
23. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781-8.
24. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 1993; 329:452-8. (Pubitemid 23222330)
25. Prystowsky EN, Freeland S, Branyas NA et al. Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2003; 14:S287-90.
26. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996; 348:7-12.
27. Singh S, Zoble RG, Yellen L et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation. 2000; 102:2385-90.
28. Stambler BS, Wood MA, Ellenbogen KA et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996; 94:1613-21. (Pubitemid 26320266)
29. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000; 342:913-20. (Pubitemid 30177051)
30. Morrow JP, Cannon CP, Reiffel JA. New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond? Am Heart J. 2007; 154:824-9.
31. Fedida D, Orth P, Chen J et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005; 16:1227-38.
32. Dorian P, Mangat I, Korley V et al. Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Can J Cardiol. 2004; 20:198D.
33. Dorian P, Pinter A, Mangat I et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007; 50:35-40. (Pubitemid 47220444)
34. Ezrin AM, Grant SM, Bell G et al. A dose-ranging study of RSD1235, a novel antiarrhythmic agent, in healthy volunteers. Pharmacologist. 2002; 44(suppl 1):A15. Abstract.
35. Roy D, Rowe BH, Stiell IG et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004; 44:2355-61. (Pubitemid 39647610)
36. Astellas Pharma US, Inc. Kynapid, vernakalant hydrochloride injection. NDA 22-034. www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4327b1-01- astellasbackgrounder. pdf (accessed 2008 Sep 4).
37. Mao ZL, Wheeler JJ, Clohs L et al. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression on other factors. J Clin Pharmacol. 2009; 49:17-29.
38. Roy D, Pratt C, Torp-Pedersen C et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. Circulation. 2008; 117:1518-25.
39. Cardiome Pharma Corp. Vernakalant (intravenous). www.cardiome.com/ vernakalantIntravenous.php (accessed 2008 Dec 30).
40. Stiell IG, Rowe BH, Roy D. RSD1235 in the treatment of recent onset atrial fibrillation in ACT I (Atrial arrhythmia Conversion Trial I) - effect of age, sex, and prior rate control medications. Ann Emerg Med. 2005; 46:S115. Abstract.
41. Kowey PR, Roy D, Pratt CM et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery. Circulation. 2007; 116:II636-7. Abstract.
42. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 2006; 114:e257-354.
43. Khan IA, Mehta JH, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003; 89:239-48. (Pubitemid 36588945)
44. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003; 87:121-8. (Pubitemid 36135964)
45. Ellenbogen KA, Stambler BS, Wood MA et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation. J Am Coll Cardiol. 1996; 28:130-6.
46. Stambler BS, Wood MA, Ellenbogen KA et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996; 94:1613-21. (Pubitemid 26320266)
47. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001; 37:542-7.